Advertisement

Calcified Tissue International

, Volume 79, Issue 2, pp 84–94 | Cite as

Fracture Risk Associated with Use of Nonsteroidal Anti-Inflammatory Drugs, Acetylsalicylic Acid, and Acetaminophen and the Effects of Rheumatoid Arthritis and Osteoarthritis

  • P. Vestergaard
  • L. Rejnmark
  • L. Mosekilde
Article

Abstract

We studied the effects of various nonmorphine pain medications as well as rheumatoid arthritis and osteoarthritis on fracture risk in a nationwide case-control study. Cases were all subjects with any fracture sustained during the year 2000 (n = 124,655) in Denmark. For each case, three controls (n = 373,962) matched on age and gender were randomly drawn from the background population. The primary exposure variables were use of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), or acetylsalicylic acid (ASA). Adjustments were made for several confounders. The effect of dose was examined by stratifying for cumulated dose (defined daily dose, DDD). For acetaminophen, a small increase in overall fracture risk was observed with use within the last year (odds ratio [OR] = 1.45, 95% confidence interval [CI] 1.41–1.49). For ASA, no increase in overall fracture risk was present with recent use. Significant heterogeneity was present for the NSAIDs; e.g., ibuprofen was associated with an increased overall fracture risk (OR = 2.09, 95% CI 2.00–2.18 for <20 DDD), while celecoxib was not (OR = 0.76, 95% CI 0.51–1.13 for <20 DDD, 2P < 0.01 for comparison). Osteoarthritis was associated with a decreased risk of any fracture if the diagnosis had been made more than 1 year ago (OR = 0.70, 95% CI 0.67–0.72). Rheumatoid arthritis was associated with an increase in overall fracture risk if the diagnosis had been made within the last year (OR = 1.86, 95% CI 1.68–2.07). Weak analgesics may be associated with fracture risk in a varying way. The effects in most cases were small. Falls may be one reason for the increase in fracture risk with some NSAIDs.

Keywords

Fracture Nonsteroidal anti-inflammatory drug Acetaminophen Risk Rheumatoid arthritis Osteoarthritis 

Notes

Acknowledgment

Danmarks Statistik (Statistics Denmark) is acknowledged for the help without which this project would not have been possible. Research librarian Ms. Edith Clausen is acknowledged for invaluable help with the references. The Danish Medical Research Council granted financial support (grant 22-04-0495).

References

  1. 1.
    Raisz LG (2001) Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 110(suppl 3A):43S–45SPubMedCrossRefGoogle Scholar
  2. 2.
    Raisz LG (1999) Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 7:419–421PubMedCrossRefGoogle Scholar
  3. 3.
    Raisz LG (1995) Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J Nutr 125:2024S–2027SPubMedGoogle Scholar
  4. 4.
    Kawaguchi H, Pilbeam CC, Harrison JR, et al. (1995) The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 313:36–46PubMedGoogle Scholar
  5. 5.
    Warner TD, Guiliano F, Vojnovic I, et al. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96:7563–7568PubMedCrossRefGoogle Scholar
  6. 6.
    Carbone LD, Tylavsky FA, Cauley JA, et al. (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18:1795–1802PubMedCrossRefGoogle Scholar
  7. 7.
    Bauer DC, Orwoll ES, Fox KM, et al. (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:29–35PubMedGoogle Scholar
  8. 8.
    Morton DJ, Barrett-Connor EL, Schneider DL (1998) Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res 13:1924–1931PubMedCrossRefGoogle Scholar
  9. 9.
    van Staa TP, Leufkens HG, Cooper C (2000) Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone 27:563–568PubMedCrossRefGoogle Scholar
  10. 10.
    Beck A, Krischak G, Sorg T, et al. (2003) Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch Orthop Trauma Surg 123:327–332PubMedCrossRefGoogle Scholar
  11. 11.
    Cooper C, Coupland C, Mitchell M (1995) Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49–52PubMedGoogle Scholar
  12. 12.
    Cortet B, Flipo RM, Duquesnoy B, et al. (1995) Bone tissue in rheumatoid arthritis (1). Bone mineral density and fracture risk. Rev Rhum Engl Ed 62:197–204PubMedGoogle Scholar
  13. 13.
    Lane NE, Pressman AR, Star VL, et al. (1995) Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 10:257–263PubMedCrossRefGoogle Scholar
  14. 14.
    Belmonte-Serrano MA, Bloch DA, Lane NE, et al. (1993) The relationship between spinal and peripheral osteoarthritis and bone density measurements. J Rheumatol 20:1005–1013PubMedGoogle Scholar
  15. 15.
    Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398–2399PubMedCrossRefGoogle Scholar
  16. 16.
    Andersen TF, Madsen M, Jørgensen J, et al. (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268PubMedGoogle Scholar
  17. 17.
    Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 156:1–10PubMedCrossRefGoogle Scholar
  18. 18.
    Wacholder S, McLaughlin JK, Silverman DT, et al. (1992) Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135:1019–1028PubMedGoogle Scholar
  19. 19.
    Capella D (1993) Descriptive tools and analysis. In: Dukes MNG (ed) Drug Utilization Studies: Methods and Uses. WHO Regional Publications, European Series 45, Copenhagen, pp 55–78Google Scholar
  20. 20.
    Nielsen GL, Sørensen HT, Zhou W, et al. (1997) The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 10:203–205Google Scholar
  21. 21.
    Charlson ME, Pompei P, Ales KL, et al. (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383PubMedCrossRefGoogle Scholar
  22. 22.
    de Groot V, Beckerman H, Lankhorst GJ, et al. (2003) How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 56:221–229PubMedCrossRefGoogle Scholar
  23. 23.
    Munk-Jørgensen P, Mortensen PB (1997) The Danish Psychiatric Central Register. Dan Med Bull 44:82–84PubMedGoogle Scholar
  24. 24.
    Miettinen OS (1985) Theoretical Epidemiology: Principles of Occurrence Research in Medicine. John Wiley & Sons, New YorkGoogle Scholar
  25. 25.
    Vestergaard P, Mollerup CL, Frøkjær VG, et al. (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321:598–602PubMedCrossRefGoogle Scholar
  26. 26.
    Shearn MA (1987) Nonsteroidal anti-inflammatory agents; nonopiate analgesics; drugs used in gout. In: Katzung BG (ed), Basic and Clinical Pharmacology. Appleton & Lange, Norwalk, pp 396–413Google Scholar
  27. 27.
    Aisen PS, Schafer KA, Grundman M, et al. (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819–2826PubMedCrossRefGoogle Scholar
  28. 28.
    Silberstein S, Tepper S, Brandes J, et al. (2004) Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 62:1552–1557PubMedGoogle Scholar
  29. 29.
    Lovell SJ, Taira T, Rodriguez E, et al. (2004) Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. Acad Emerg Med 11:1278–1282PubMedCrossRefGoogle Scholar
  30. 30.
    Boyle M, Hundy S, Torda TA (1997) Paracetamol administration is associated with hypotension in the critically ill. Aust Crit Care 10:120–122PubMedGoogle Scholar
  31. 31.
    Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedGoogle Scholar
  32. 32.
    Biering Sorensen F, Bohr HH, Schaadt OP (1990) Longitudinal study of bone mineral content in the lumbar spine, the forearm and the lower extremities after spinal cord injury. Eur J Clin Invest 20:330–335PubMedGoogle Scholar
  33. 33.
    Cauley JA, Fullman RL, Stone KL, et al. (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporosis Int 16:1525–1537CrossRefGoogle Scholar
  34. 34.
    Schneider DL, Barrett-Connor E, Morton DJ, et al. (2002) Bone mineral density and clinical hand osteoarthritis in elderly men and women: the Rancho Bernardo study. J Rheumatol 29:1467–1472PubMedGoogle Scholar
  35. 35.
    Hall GM, Spector TD, Griffin AJ, et al. (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510–1516PubMedGoogle Scholar
  36. 36.
    Kroger H, Honkanen R, Saarikoski S, et al. (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 53:18–23PubMedCrossRefGoogle Scholar
  37. 37.
    Hoidrup S, Grønbæk M, Gottschau A, et al. (1999) Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 149:993–1001PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of Endocrinology and MetabolismAarhus Sygehus, Aarhus University HospitalAarhus CDenmark

Personalised recommendations